Evidence map›Paper›PMID 27239760›Full record

ArticleNature medicine2016

PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals.

Riddhima Banga, Francesco Andrea Procopio, Alessandra Noto, Georgios Pollakis, Matthias Cavassini, Khalid Ohmiti, Jean-Marc Corpataux, Laurence de Leval, Giuseppe Pantaleo, Matthieu Perreau

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03468582 (Pilot Study Using 123I Radiolabeled 3BNC117 SPECT/CT to Image HIV Reservoir in Chronically Infected HIV Patients), which is not on this map. Cited by 339 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
339citing papers in PubMed, 2 pooled it
34.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03468582 early_phase1completednot on this mapstarted 2018, after this paper: background citation

Pilot Study Using 123I Radiolabeled 3BNC117 SPECT/CT to Image HIV Reservoir in Chronically Infected HIV Patients

TypeinterventionalSponsorUniversity of Lausanne HospitalsRan2018 to 2020Enrolled6ConditionsHuman Immunodeficiency VirusArms123I radiolabeled 3BNC117
3 · Its place in the literature

Who cites it

339 citing papers in PubMed, 2 syntheses or guidelines pooled it, 463 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Renaissance of antiviral CD8Nature reviews. Immunology · 2026
    Review
  8. Article
  9. Review
  10. HIV controllers, lessons learnt from the lymphoid tissues.Current opinion in HIV and AIDS · 2026
    Review
  11. Review
  12. Targeting PD-1Science advances · 2026
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

279 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Riddhima BangaService of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Francesco Andrea ProcopioService of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Alessandra NotoService of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Georgios PollakisDepartment of Clinical Infection, Microbiology and Immunology (CIMI), Institute of Infection and Global Health (IGH), University of Liverpool, Liverpool, UK.
Matthias CavassiniService of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Khalid OhmitiService of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Jean-Marc CorpatauxService of Vascular Surgery, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Laurence de LevalInstitute of Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Giuseppe PantaleoService of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Matthieu PerreauService of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
University of Lausanne · CHSwiss Vaccine Research Institute · CHUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanisms responsible for the persistence of HIV-1 after many years of suppressive antiretroviral therapy (ART) have been only partially elucidated. Most of the studies investigating HIV-1 persistence have been performed with blood, although it is well known that germinal centers (GCs) within lymph nodes (LNs) serve as primary sites for HIV-1 replication. We sought to identify the memory CD4 T cell populations in blood and LNs that are responsible for the production of replication-competent and infectious HIV-1, as well as for active and persistent virus transcription in ART-treated (for 1.5-14.0 years), aviremic (<50 HIV RNA copies/ml) HIV-infected individuals. We demonstrate that LN CD4 T cells that express programmed cell death 1 (PDCD1; also known as PD-1), which are composed of about 65% T follicular helper cells as defined by the expression of the cell surface receptors CXCR5 and PD-1, are the major source of replication-competent HIV-1 and of infectious virus, as compared to any other (CXCR5(-)PD-1(-) and CXCR5(+)PD-1(-)) blood or LN memory CD4 T cell populations. LN PD-1(+) cells accounted for 46% and 96% of the total pools of memory CD4 T cells containing inducible replication-competent or infectious virus, respectively. Notably, higher levels of cell-associated HIV-1 RNA were present in LN PD-1(+) cells after long-term (up to 12 years) ART than in other memory CD4 T cell subpopulations. These results indicate that LN PD-1(+) cells are the major CD4 T cell compartment in the blood and LNs for the production of replication-competent and infectious HIV-1, and for active and persistent virus transcription in long-term-ART-treated aviremic individuals. Thus, these cells may represent a major obstacle to finding a functional cure for HIV-1 infection.

Indexed as

Antiretroviral Therapy, Highly ActiveVirus ReplicationAdultCase-Control StudiesCD4-Positive T-LymphocytesFemaleHIV-1HIV InfectionsHumansLymph NodesMaleMiddle AgedProgrammed Cell Death 1 ReceptorReceptors, CXCR5RNA, ViralT-Lymphocytes, Helper-InducerCXCR5 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, CXCR5RNA, Viral

Identifiers

PMID27239760
OpenAlexW2414537326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.